Search results for "coronary syndrome"

showing 10 items of 281 documents

Antiplatelets in acute coronary syndrome in Poland – from guidelines to clinical practice

2021

Acute coronary syndrome is a factor for poor prognosis and recurrent cardiovascular events. Adequate antiplatelet therapy is crucial in patients with the acute coronary syndrome for risk reduction. Such treatment is well described in four documents issued by the European Society of Cardiology, which precisely illustrate the use of antiplatelets in the settings of ST-elevated and non-ST elevated myocardial infarction. Despite its unquestioned role in the treatment of acute coronary syndrome, recent real-world-data from Polish registries reveal poor adherence to the guidelines-recommended antiplatelet treatment in Poland. Thus, we present here a comprehensive review of the use of antiplatelet…

Poor prognosismedicine.medical_specialtyAcute coronary syndromeReview Paperbusiness.industryRInvasive cardiologymedicine.diseaseantiplatelet treatmentnon-ST elevation myocardial infarctionPoor adherenceClinical PracticeST elevation myocardial infarctionmedicineMedicineIn patientNational registryMyocardial infarctionguidelinesCardiology and Cardiovascular MedicineIntensive care medicinebusinessPostępy w Kardiologii Interwencyjnej = Advances in Interventional Cardiology
researchProduct

Editor's Choice - Frailty and the management of patients with acute cardiovascular disease:A position paper from the Acute Cardiovascular Care Associ…

2018

Frailty is increasingly seen among patients with acute cardiovascular disease. A combination of an ageing population, improved disease survival, treatable long-term conditions as well as a greater recognition of the syndrome has accelerated the prevalence of frailty in the modern world. Yet, this has not been matched by an expansion of research. National and international bodies have identified acute cardiovascular disease in the frail as a priority area for care and an entity that requires careful clinical decisions, but there remains a paucity of guidance on treatment efficacy and safety, and how to manage this complex group. This position paper from the Acute Cardiovascular Care Associa…

Population ageingmedicine.medical_specialtyCritical Careheart failureCardiovascular careDisease030204 cardiovascular system & hematologyCritical Care and Intensive Care Medicine03 medical and health sciences0302 clinical medicineacute cardiovascular caremedicineHumansacute coronary syndromesatrial fibrillation030212 general & internal medicineIntensive care medicineFrailtybusiness.industryAtrial fibrillationGeneral Medicinemedicine.diseaseTreatment efficacyAcute cardiovascular diseasecritical careTreatment OutcomeCardiovascular DiseasesHeart failureAcute DiseasePosition paperCardiology and Cardiovascular Medicinebusiness
researchProduct

[Pharmacological prevention of coronary relapses in Italian clinical practice: a literature review]. La prevenzione farmacologica delle recidive coro…

2012

Scientific advances in cardiovascular research during the last decades have afforded effective pharmacological treatment to those surviving their first acute myocardial infarction. This secondary prevention treatment, based upon the combined administration of statins, aspirin, beta-blockers and renin-angiotensin blockers, might avert great part of the relapses contributing substantially to the overall incidence of acute coronary syndromes in the general population. However, a treatment gap separates evidence-based recommendations from their daily clinical application, a condition frequently explored even in the Italian medical setting. However, a general overview of the problem is missing i…

Prevention acute coronary syndromeSettore MED/11 - Malattie Dell'Apparato Cardiovascolare
researchProduct

Cardiovascular Events in Moderately to Severely Obese Obstructive Sleep Apnea Patients on Positive Airway Pressure Therapy.

2016

<b><i>Background:</i></b> In moderately to severely obese patients with obstructive sleep apnea (OSA), the effects of long-term positive airway pressure (PAP) treatment on cardiovascular risk are poorly defined. <b><i>Purpose:</i></b> To assess the effect of continuous positive airway pressure (CPAP) or noninvasive ventilation (NIV) on the occurrence of cardiovascular events in obese OSA patients. <b><i>Methods:</i></b> We performed a noninterventional observational study in obese OSA patients recruited between 2007 and 2010 at the Sleep Center, University of Grenoble, treated with CPAP or NIV, and followed for 5.6 year…

Pulmonary and Respiratory MedicineAdultMalemedicine.medical_treatmentMyocardial Infarctionmacromolecular substancesComorbiditySettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologySeverity of Illness Index03 medical and health sciences0302 clinical medicineSleep and breathingRisk FactorsSeverity of illnessPositive airway pressuremedicineMyocardial RevascularizationHumansContinuous positive airway pressureMyocardial infarctionAngina UnstableObesityAcute Coronary SyndromeStrokeAgedSleep-disordered breathing · Longitudinal studies · Continuous positive airway pressure · Noninvasive ventilation · PrognosisSleep Apnea ObstructiveContinuous Positive Airway Pressurebusiness.industryArrhythmias CardiacMiddle Agedmedicine.diseaseObesityrespiratory tract diseasesObstructive sleep apneaStroke030228 respiratory systemCardiovascular DiseasesAnesthesiaFemalebusinessRespiration; international review of thoracic diseases
researchProduct

Obstructive sleep apnoea in acute coronary syndrome.

2019

Obstructive sleep apnoea (OSA) syndrome affects about 13% of the male and 7–9% of the female population. Hypoxia, oxidative stress and systemic inflammation link OSA and cardiovascular and metabolic consequences, including coronary artery disease. Current research has identified several clinical phenotypes, and the combination of breathing disturbances during sleep, systemic effects and end-organ damage might help to develop personalised therapeutic approaches. It is unclear whether OSA is a risk factor for acute coronary syndrome (ACS) and might affect its outcome. On the one hand, OSA in patients with ACS may worsen prognosis; on the other hand, OSA-related hypoxaemia could favour the dev…

Pulmonary and Respiratory MedicineMaleAcute coronary syndromemedicine.medical_specialtymedicine.medical_treatmentSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologySystemic inflammationCoronary artery disease03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinePositive airway pressurePrevalenceMedicineHumansContinuous positive airway pressureNon disponibiliAcute Coronary SyndromeAdverse effectLunglcsh:RC705-779Sleep Apnea ObstructiveContinuous Positive Airway Pressurebusiness.industryRespirationHemodynamicsSleep apnealcsh:Diseases of the respiratory systemHypoxia (medical)medicine.diseasenervous system diseasesrespiratory tract diseasesTreatment Outcome030228 respiratory systemCardiologyPatient ComplianceFemalemedicine.symptombusinessSleepEuropean respiratory review : an official journal of the European Respiratory Society
researchProduct

Exercise ECG Testing and Stress Cardiac Magnetic Resonance for Risk Prediction in Patients With Chronic Coronary Syndrome

2021

Vasodilator stress cardiac magnetic resonance (VS-CMR) has become crucial in the workup of patients with known or suspected chronic coronary syndrome (CCS). Whether traditional exercise ECG testing (ExECG) contributes prognostic information beyond VS-CMR is unclear.We retrospectively included 288 patients with known or suspected CCS who had undergone ExECG and subsequent VS-CMR in our institution. Clinical, ExECG, and VS-CMR variables were recorded. We defined the serious adverse events (SAE) as a combined endpoint of acute coronary syndrome, admission for heart failure, or all-cause death.During a mean follow-up of 4.2 ± 2.15 yr, we registered 27 SAE (15 admissions for acute coronary syndr…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyAcute coronary syndromeMagnetic Resonance SpectroscopyVasodilator stressCoronary Artery DiseaseRisk AssessmentElectrocardiographyPredictive Value of TestsRisk FactorsInternal medicineHumansMedicineExercise ecgIn patientAdverse effectRetrospective Studiesbusiness.industryRehabilitationPrognosismedicine.diseaseHeart failurecardiovascular systemCardiologyCardiology and Cardiovascular MedicinebusinessCardiac magnetic resonancePerfusionJournal of Cardiopulmonary Rehabilitation and Prevention
researchProduct

COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction

2022

ObjectiveThe initial data of the International Study on Acute Coronary Syndromes - ST Elevation Myocardial Infarction COVID-19 showed in Europe a remarkable reduction in primary percutaneous coronary intervention procedures and higher in-hospital mortality during the initial phase of the pandemic as compared with the prepandemic period. The aim of the current study was to provide the final results of the registry, subsequently extended outside Europe with a larger inclusion period (up to June 2020) and longer follow-up (up to 30 days).MethodsThis is a retrospective multicentre registry in 109 high-volume primary percutaneous coronary intervention (PPCI) centres from Europe, Latin America, S…

RegistrieMaleST Elevation Myocardial Infarction/diagnosisTime FactorsPercutaneousmedicine.medical_treatmentVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Coronary Artery DiseasePractice Patterns030204 cardiovascular system & hematologyRate ratioTime-to-Treatment/trendsCardiologists0302 clinical medicineRetrospective StudieHeart RateRisk FactorsPandemicST segmentRegistriesHospital Mortality030212 general & internal medicineMyocardial infarctionPractice Patterns Physicians'10. No inequalityPercutaneous Coronary Intervention/adverse effectsHospital Mortality/trendsCOVID-19; myocardial infarction; percutaneous coronary interventionIncidenceIncidence (epidemiology)*percutaneous coronary interventionMiddle Aged3. Good healthTreatment Outcomemyocardial infarctionCardiologyFemale*COVID-19Cardiology and Cardiovascular MedicineCardiologists/trendsHumanCOVID-19; myocardial infarction; percutaneous coronary intervention; Aged; Cardiologists; Female; Hospital Mortality; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Practice Patterns Physicians'; Registries; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Time-to-Treatment; Treatment Outcome; COVID-19medicine.medical_specialtyTime FactorCoronavirus disease 2019 (COVID-19)CardiologistRisk AssessmentTime-to-Treatment03 medical and health sciencesInternal medicinemedicineHumansAcute Coronary SyndromePandemicsRetrospective StudiesAgedPhysicians'SARS-CoV-2business.industryRisk FactorCOVID-19 myocardial infarction percutaneous coronary interventionpercutaneous coronary interventionPercutaneous coronary interventionCOVID-19*myocardial infarctionmedicine.diseasePractice Patterns Physicians'/trendsST Elevation Myocardial Infarctionbusiness
researchProduct

Incidence and prognostic factors related to major adverse cerebrovascular events in patients with complex aortic diseases treated by the chimney tech…

2018

Abstract Objective Endovascular aneurysm repair (EVAR) with the chimney technique (ch-EVAR) has been used for the treatment of aortic aneurysms as an alternative approach to fenestrated endografting or open repair. Nonetheless, the need for an upper extremity arterial access may contribute to a higher risk for periprocedural cerebrovascular events. This study reports on the perioperative cerebral and major adverse cardiac and cerebrovascular events (MACCE) after ch-EVAR. Methods The PERICLES registry (PERformance of the chImney technique for the treatment of Complex aortic pathoLogiES) is an international, retrospective multicenter study evaluating the performance of ch-EVAR for the treatme…

RegistrieMaleTime Factorsmedicine.medical_treatment030204 cardiovascular system & hematologySettore MED/22 - Chirurgia VascolareEndovascular aneurysm repair0302 clinical medicineRetrospective StudieRisk FactorsCause of DeathCarotid artery diseaseOdds RatioRegistries030212 general & internal medicineMultivariate AnalysiStrokeCause of deathAged 80 and overIncidenceEndovascular ProceduresAtrial fibrillationchimney technique; stroke; aortic archMiddle AgedStrokeHeart DiseaseTreatment OutcomeIschemic Attack TransientCerebrovascular DisorderCardiologyFemaleCardiology and Cardiovascular MedicineHumanAdultmedicine.medical_specialtyAcute coronary syndromeLogistic ModelTime FactorHeart DiseasesOperative TimeAortic DiseasesBlood Vessel Prosthesis Implantation03 medical and health sciencesInternal medicinemedicineHumanscardiovascular diseasesAgedRetrospective StudiesEndovascular ProcedureChi-Square Distributionbusiness.industryRisk FactorOdds ratioPerioperativeAortic Diseasemedicine.diseaseSurgeryCerebrovascular DisordersLogistic ModelsMultivariate AnalysisSurgerybusiness
researchProduct

Moderne Therapie bei akutem Koronarsyndrom

2002

Inhibition of platelet aggregation with aspirin and anticoagulation with unfractionated heparin can be considered the gold standard treatment of patients with acute coronary syndromes. Replacement of unfractionated heparins by low-molecular weight heparins seem to further improve the cardiovascular risk. Additional treatment with glycoprotein IIb/IIIa receptor blockers led to a further reduction of the clinical event rate, especially in patients undergoing coronary interventions during an acute coronary syndrome (more than 30% relative risk reduction). However, the latter substances did only lead to marginal improvements in the setting of a conservative stabilization of patients with acute …

Relative risk reductionAcute coronary syndromeAspirinmedicine.medical_specialtybusiness.industryUnstable anginaGeneral Medicinemedicine.diseaseClopidogrelCoronary artery diseaseAnginaInternal medicineCardiologyMedicineMyocardial infarctionbusinessmedicine.drugMedizinische Klinik
researchProduct

Effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pne…

2007

Annual circulation of influenza virus coincides with a peak in cardiovascular and pneumonia mortality/morbidity. This study aimed to determine the effectiveness of MF59-adjuvanted subunit influenza vaccine in preventing hospitalisation due to acute coronary syndrome (ACS), cerebrovascular accident (CVA) and pneumonia in the elderly. Three case-control studies were performed during the 2004-2005 influenza season in three health districts in Valencia, Spain (total elderly [>64 years of age] population: n=105,454). Controls were patients admitted for an acute surgical process or trauma within 10 days of case admission. In total, 159 patients were hospitalised for ACS, 148 for CVA and 242 for p…

Relative risk reductionSqualeneAcute coronary syndromemedicine.medical_specialtyInfluenza vaccinePopulationPolysorbatesMass VaccinationAdjuvants ImmunologicRisk FactorsInternal medicinemedicineHumanseducationAgedAged 80 and overeducation.field_of_studyGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryRespiratory diseasePublic Health Environmental and Occupational HealthOdds ratioPneumoniamedicine.diseaseVaccinationHospitalizationPneumoniaCerebrovascular DisordersInfectious DiseasesCardiovascular DiseasesInfluenza VaccinesSpainCase-Control StudiesImmunologyVaccines SubunitMolecular MedicinebusinessVaccine
researchProduct